Illustrative image.

Kevzara

Name: Kevzara
Brand: Sanofi
Availability: InStock

Sarilumab

Prescription required

$5385.00

150mg · 3 × 2 pre-filled pen · 3 months supply

BrandBranded medicine· By Sanofi

$1795.00 per month

Strength

How long a supply?

1 month$1795.00 a monthOne-off$1795.00

3 months$1795.00 a monthOne-off$5385.00

6 months$1795.00 a monthOne-off$10770.00

Supplied from Israel

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Annual cost

$23335a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

150mg

200mg

FDA boxed warningRisk of serious infections

Patients treated with KEVZARA are at increased risk for developing serious infections that may lead to hospitalization or death. Opportunistic infections have also been reported in patients receiving KEVZARA. Most patients who developed infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Avoid use of KEVZARA in patients with an active infection.

Reported infections include:

Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before KEVZARA use and during therapy. Treatment for latent infection should be initiated prior to KEVZARA use.

Invasive fungal infections, such as candidiasis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.

Bacterial, viral and other infections due to opportunistic pathogens.

Closely monitor patients for signs and symptoms of infection during treatment with KEVZARA. If a serious infection develops, interrupt KEVZARA until the infection is controlled.

Consider the risks and benefits of treatment with KEVZARA prior to initiating therapy in patients with chronic or recurrent infection.

Serious infections leading to hospitalization or death including bacterial, viral, invasive fungal, and other opportunistic infections have occurred in patients receiving KEVZARA.

Cases of tuberculosis (TB) have been reported. Prior to starting KEVZARA, test for latent TB; if positive, start treatment for TB.

Read this with the rest of the clinical information

About Kevzara

Overview

Kevzara (sarilumab) is a prescription medicine supplied in a pre-filled syringe or pre-filled pen for injection under the skin. It treats adults with moderately to severely active rheumatoid arthritis when one or more disease-modifying antirheumatic drugs have not worked well enough or were not tolerated, and adults with polymyalgia rheumatica when corticosteroids have not worked well enough or cannot be tolerated as they are reduced. It also treats active polyarticular juvenile idiopathic arthritis in patients weighing at least 63 kg. It works by blocking receptors for interleukin-6 (IL-6), a protein involved in inflammation.

What it treats

- Moderately to severely active rheumatoid arthritis in adults who have not responded adequately to, or cannot tolerate, one or more disease-modifying antirheumatic drugs (DMARDs). - Polymyalgia rheumatica in adults who have not responded adequately to corticosteroids or cannot tolerate a gradual reduction in corticosteroid treatment. - Active polyarticular juvenile idiopathic arthritis in patients weighing at least 63 kg.

Safety information

Side effects

Common side effects vary by the condition being treated. In rheumatoid arthritis, they include low neutrophil counts (a type of white blood cell), increased ALT liver enzyme levels, redness at the injection site, upper respiratory infections and urinary tract infections. In polymyalgia rheumatica, common effects include low neutrophil or overall white blood cell counts and itching at the injection site. In polyarticular juvenile idiopathic arthritis, common effects include nose and throat infections, low neutrophil counts, upper respiratory infections and redness at the injection site. Serious side effects include serious infections, suppression of the immune system, low neutrophil or platelet counts, increased liver enzymes, abnormal blood fat levels, allergic reactions and a tear in the stomach or intestinal wall (gastrointestinal perforation). Contact a doctor promptly if you develop an infection, an allergic reaction or sudden abdominal pain. The risk of gastrointestinal perforation may be higher with diverticulitis or use of NSAIDs or corticosteroids. Blood tests are needed to monitor blood cell counts, liver enzymes and blood fat levels.

FDA boxed warning

Risk of serious infections

Avoid use of KEVZARA in patients with an active infection.

Reported infections include:

Invasive fungal infections, such as candidiasis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.

Bacterial, viral and other infections due to opportunistic pathogens.

Closely monitor patients for signs and symptoms of infection during treatment with KEVZARA. If a serious infection develops, interrupt KEVZARA until the infection is controlled.

Consider the risks and benefits of treatment with KEVZARA prior to initiating therapy in patients with chronic or recurrent infection.

Serious infections leading to hospitalization or death including bacterial, viral, invasive fungal, and other opportunistic infections have occurred in patients receiving KEVZARA.

Cases of tuberculosis (TB) have been reported. Prior to starting KEVZARA, test for latent TB; if positive, start treatment for TB.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for sudden abdominal pain. - Contact your doctor immediately if you develop signs or symptoms of an infection. - Seek immediate medical attention if you have an allergic reaction.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not use Kevzara if you have a known allergy to sarilumab or any of its inactive ingredients. Avoid use during an active infection because of the risk of serious infections. Kevzara requires blood tests to monitor neutrophils (a type of white blood cell), platelets, liver enzymes and blood lipids. It may cause low neutrophil or platelet counts, raised liver enzymes and abnormal lipid levels. The risk of a tear in the stomach or intestinal wall may be higher if you have diverticulitis or also use NSAIDs or corticosteroids. Seek prompt medical assessment for sudden abdominal pain or other acute abdominal symptoms. Allergic reactions can occur. Avoid live vaccines while using Kevzara. If you are breastfeeding, discuss with your prescriber whether to stop Kevzara or stop breastfeeding, taking into account the importance of treatment to you.

Using Kevzara

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label KEVZARA (SARILUMAB) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.